When will you choose Tarlatamab over an alternative systemic therapy (e.g. lurbinectedin, topotecan) for relapsed ES SCLC?

In which patient types would you prioritize Tarlatamab first over alternative systemic therapy options for relapsed ES SCLC?

• Younger patients
• ECOG 0
• No response to initial platinum
• Recurrence <6 mos from platinum
• Recurrence <12 mos from platinum
• Low disease burden
• High disease burden
• Presence of CNS mets
• Absence of CNS mets
• I prioritize earlier use for all patients
• I need more long term data to choose Tarlatamab over another systemic treatment
• I never choose Tarlatamab over an alternate systemic therapy option
• Other